Shares of Indegene (NSE: INDGN) surged to a 52-week high on September 29, 2026, as multiple brokerage firms began coverage on the digital life sciences company, forecasting substantial upside potential for the stock.
Analysts See Significant Upside for Indegene
Domestic brokerage firms have expressed a positive outlook on Indegene Ltd., with new analyst reports suggesting an upside potential of up to 25 percent from Tuesday's low. This renewed interest propelled the stock to its highest point in a year.
Indegene's stock notably recovered more than 3.2 percent from its intraday low of Rs 607.50, hitting a 52-week high of Rs 627. The company's market capitalization now stands close to Rs 15,000 crore. Since its 52-week low of Rs 414.90 on March 23, 2026, the stock has appreciated by over 50 percent.
The company made its stock market debut in May 2024, raising Rs 1,842 crore through its IPO, with shares priced at Rs 452 each. The stock currently trades approximately 38 percent above its initial public offering price.
Shareholding Structure and Company Profile
As of June 30, 2026, Indegene's shareholding pattern indicates that 100 percent of its shares are held by public shareholders, with no identifiable promoters. Mutual funds collectively own more than 5.28 percent, while Foreign Portfolio Investors (FPIs) hold over 9.91 percent of the company.
Significantly, five key shareholders, who also serve as top executives, collectively owned 27.79 percent of Indegene's shares as of the same date. Retail investors, comprising over 1.31 lakh individuals, hold nearly 12.50 percent of the company's equity.
Founded in 1998, Indegene operates as a digital-first commercialization partner for the global life sciences industry. The company serves 20 of the top biopharma companies and maintains a presence across 80 markets, with delivery and operational centers in over 11 countries. Indegene leverages deep life-sciences domain expertise, proprietary technology, artificial intelligence (AI), and data analytics to streamline complex and highly regulated workflows.
Brokerage Targets and Industry Outlook
Analysts at ICICIDirect Research have issued a 'buy' recommendation for Indegene, setting a target price of Rs 750. They highlight the supportive underlying pharma market, with global revenues projected to exceed $2 trillion by 2030. Management anticipates the global pharma industry to grow at a 5-8 percent CAGR between 2026 and 2028. Factors such as patent expiries, pricing pressures, and productivity demands are expected to drive further outsourcing adoption in life sciences operations.
ICICIDirect also noted encouraging early productivity indicators, with AI-related revenue standing at $400 million and a near-term opportunity exceeding $500 million. They project EBITDA margins of 17.7 percent, 19 percent, and 19 percent for FY27E, FY28E, and FY29E, respectively, driven by operating leverage and improved revenue productivity.
Similarly, Axis Securities initiated coverage with a 'Buy' recommendation and a target price of Rs 705. They foresee a robust growth trajectory for Indegene, fueled by expanding client wallet share, successful deal conversions, new business acquisitions, and AI-led offerings. Axis Securities expects operating leverage and the normalization of investment-related costs to enable earnings growth to outpace revenue growth.